Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership

Core Insights - Dyadic International, Inc. has entered into a partnership with Proliant Health and Biologicals (PHB) to develop and commercialize animal-free recombinant albumin products, with an upfront milestone payment of $1.5 million and profit-sharing from sales [2][3][12] - The partnership aims to target the approximately $6 billion serum albumin market, focusing initially on recombinant human serum albumin products, with the first product expected to launch in the first half of 2025 [2][3] - Dyadic's protein production platforms, C1 and Dapibus™, utilize the fungus Thermothelomyces heterothallica to produce high-quality proteins sustainably and cost-effectively, supporting applications in various sectors including life sciences and next-generation foods [4][7] Company Overview - Dyadic International is a biotechnology company focused on innovative microbial protein production to meet the growing demand for cost-effective recombinant proteins across industrial, animal health, and human health applications [7] - Proliant Health & Biologicals is a leading supplier of purified proteins, committed to high standards of consistency, traceability, and quality in the market, and is the world's largest manufacturer of purified bovine proteins [5][14] Market Context - The partnership is a strategic move to address the increasing interest and demand for alternative protein sources in the diagnostic and life sciences industries, allowing PHB to expand its product portfolio with animal-free options [12]